To improve the staging accuracy of patients with moderate to advanced cervical cancer and monitor the treatment effect by low-cost and noninvasive methods at the same time, the study combined MRI and serum HE4, TSGF, and CD105 in the application as follows. The gene discussed is WFDC2; the disease is cervical carcinoma.